Metabolic Syndrome, AtherosclerosisNCT01594710
Risk Factor Analysis for Developing Metabolic Syndrome in Korean Adults
An observational study of Metabolic Syndrome, Atherosclerosis, run by Korea University at 1 site in South Korea.
Trial summary
In Asia, the prevalence of metabolic syndrome have been dramatically increased. Therefore, the investigators intend to the collect the blood sample, laboratory, anthropometric, and body composition parameters prospectively to examine the risk factors of metabolic syndrome. Read more about this study
- Who is it for?
- Ages 20 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Metabolic Syndrome, Atherosclerosis
- How many people
- 1,800 participants
- Where
- 1 siteSouth Korea
- Study dates
- Feb 2012to May 2015
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 80 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Apparently healthy people who underwent medical routine check up in Korea University Helath Promotion Center.
Who may be able to join
- Apparently healthy people who underwent medical routine check up in Korea Health Promotion Center.
- age > 20 years
Who cannot join
- History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
- Stage 2 hypertension
- Severe renal or hepatic disease
Trial locations and contacts
1 site in 1 country.
About this study
In Asia, the prevalence of metabolic syndrome have been dramatically increased. Therefore, the investigators intend to the collect the blood sample, laboratory, anthropometric, and body composition parameters prospectively to examine the risk factors of metabolic syndrome. Furthermore, the investigators will collect the data of carotid IMT and branchial ankle pulse wave velocity to clarify the metabolic risk factors of atherosclerosis.
- Conditions
- Metabolic Syndrome, Atherosclerosis
- Medical subject headings
- Metabolic Syndrome, Atherosclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Apparently Health People | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The impact of various cardiovascular risk factors (inflammatory markers, hepatokines, adipokines, body composition parameters) for developing metabolic syndrome in prospective design
Measured: 36months
Secondary outcomes (1)
The relationship of various cardiovascular risk factors (inflammatory markers, hepatokines, adipokines, body composition parameters) with metabolic syndrome and atherosclerosis measured by baPWV and carotid IMT in cross sectional design
Measured: 36months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2012 (estimated)
- Study startFeb 2012
- Primary completionFeb 2015
- Study completionMay 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Metabolic Syndrome, AtherosclerosisStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,800 participants (actual)
Sponsor and investigators
- Lead sponsor
- Korea University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kyung Mook Choi, Korea University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01594710
- Sponsor's protocol ID
- KoreaHealth_MS
- Status last verified
- Apr 2014
- First submitted
- 28 Apr 2012
- Last updated
- 14 Oct 2015
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Yoo HJ, Hwang SY, Choi JH, Lee HJ, Chung HS, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. PLoS One. 2017 Apr 4;12(4):e0174717. doi: 10.1371/journal.pone.0174717. eCollection 2017.
PubMed 28376109Lee HJ, Hwang SY, Hong HC, Ryu JY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM, Yoo HJ. Waist-to-hip ratio is better at predicting subclinical atherosclerosis than body mass index and waist circumference in postmenopausal women. Maturitas. 2015 Mar;80(3):323-8. doi: 10.1016/j.maturitas.2014.12.015. Epub 2015 Jan 12.
PubMed 25631349Yoo HJ, Hwang SY, Hong HC, Choi HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM. Association of metabolically abnormal but normal weight (MANW) and metabolically healthy but obese (MHO) individuals with arterial stiffness and carotid atherosclerosis. Atherosclerosis. 2014 May;234(1):218-23. doi: 10.1016/j.atherosclerosis.2014.02.033. Epub 2014 Mar 16.
PubMed 24681911Choi KM, Hwang SY, Hong HC, Choi HY, Yoo HJ, Youn BS, Baik SH, Seo HS. Implications of C1q/TNF-related protein-3 (CTRP-3) and progranulin in patients with acute coronary syndrome and stable angina pectoris. Cardiovasc Diabetol. 2014 Jan 13;13:14. doi: 10.1186/1475-2840-13-14.
PubMed 24417980Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2014 May;59(5):1772-8. doi: 10.1002/hep.26716. Epub 2014 Mar 24.
PubMed 23996808
Study at a glance
From the registry record, last updated by the sponsor on 14 Oct 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Risk Factor Analysis for Developing Metabolic Syndrome in Korean Adults
- ClinicalTrials.gov ID
- NCT01594710
- Acronym / sponsor ID
- KoreaHealth_MS
- Conditions
- Metabolic Syndrome, Atherosclerosis
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,800 participants (actual)
- Lead sponsor
- Korea UniversityUniversity, hospital or other
- Study start
- Feb 2012
- Primary completion
- Feb 2015 (actual)
- Study completion
- May 2015 (actual)
- First posted
- 9 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In Asia, the prevalence of metabolic syndrome have been dramatically increased. Therefore, the investigators intend to the collect the blood sample, laboratory, anthropometric, and body composition parameters prospectively to examine the risk factors of metabolic syndrome. Furthermore, the investigators will collect the data of carotid IMT and branchial ankle pulse wave velocity to clarify the metabolic risk factors of atherosclerosis.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Apparently Health People | – | – |
Who may qualify
- Ages
- 20 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Apparently healthy people who underwent medical routine check up in Korea University Helath Promotion Center.
Key inclusion criteria (2 listed)
- Apparently healthy people who underwent medical routine check up in Korea Health Promotion Center.
- age > 20 years
Key exclusion criteria (3 listed)
- History of cardiovascular disease (myocardial infarction, unstable angina, stroke, or cardiovascular revascularization)
- Stage 2 hypertension
- Severe renal or hepatic disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The impact of various cardiovascular risk factors (inflammatory markers, hepatokines, adipokines, body composition parameters) for developing metabolic syndrome in prospective design
Time frame: 36months
1 secondary outcome
The relationship of various cardiovascular risk factors (inflammatory markers, hepatokines, adipokines, body composition parameters) with metabolic syndrome and atherosclerosis measured by baPWV and carotid IMT in cross sectional design
Time frame: 36months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Oct 2015.
- Derived from this study: PubMed 28376109Yoo HJ, Hwang SY, Choi JH, Lee HJ, Chung HS, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Association of leukocyte cell-derived chemotaxin 2 (LECT2) with NAFLD, metabolic syndrome, and atherosclerosis. PLoS One. 2017 Apr 4;12(4):e0174717. doi: 10.1371/journal.pone.0174717. eCollection 2017.
- Derived from this study: PubMed 25631349Lee HJ, Hwang SY, Hong HC, Ryu JY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM, Yoo HJ. Waist-to-hip ratio is better at predicting subclinical atherosclerosis than body mass index and waist circumference in postmenopausal women. Maturitas. 2015 Mar;80(3):323-8. doi: 10.1016/j.maturitas.2014.12.015. Epub 2015 Jan 12.
- Derived from this study: PubMed 24681911Yoo HJ, Hwang SY, Hong HC, Choi HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH, Choi KM. Association of metabolically abnormal but normal weight (MANW) and metabolically healthy but obese (MHO) individuals with arterial stiffness and carotid atherosclerosis. Atherosclerosis. 2014 May;234(1):218-23. doi: 10.1016/j.atherosclerosis.2014.02.033. Epub 2014 Mar 16.
- Derived from this study: PubMed 24417980Choi KM, Hwang SY, Hong HC, Choi HY, Yoo HJ, Youn BS, Baik SH, Seo HS. Implications of C1q/TNF-related protein-3 (CTRP-3) and progranulin in patients with acute coronary syndrome and stable angina pectoris. Cardiovasc Diabetol. 2014 Jan 13;13:14. doi: 10.1186/1475-2840-13-14.
- Derived from this study: PubMed 23996808Hong HC, Hwang SY, Choi HY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology. 2014 May;59(5):1772-8. doi: 10.1002/hep.26716. Epub 2014 Mar 24.
Related trials for Metabolic Syndrome, Atherosclerosis
RecruitingObservational study
Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
Metabolic Disease, Obesity
RecruitingObservational study
Study of the Effect of Innate on the Inflammatory Response to Endotoxin
Asthma, Atherosclerosis
Not yet recruitingObservational study
Associations Between Dietary Patterns, LDL Aggregation, and Cardiometabolic Health
Atherosclerosis Cardiovascular Disease, Metabolic Syndrome
Not yet recruitingPhase 4
Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease
Cardiorenal Metabolic Syndrome, Atherosclerotic Cardiovascular Disease
Active, not recruiting
The ILERVAS Project: Assessing the Prevalence of Subclinical Vascular Disease and Hidden Kidney Disease
Atherosclerosis, Chronic Kidney Diseases
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Metabolic Syndrome, Atherosclerosis, run by Korea University at 1 site in South Korea.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Oct 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The impact of various cardiovascular risk factors (inflammatory markers, hepatokines, adipokines, body composition parameters) for developing metabolic syndrome in prospective design (time frame: 36months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01594710, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Oct 2015; AzTrials last refreshed its copy on 3 Nov 2026.